Obiltoxaximab

Hypersensitivity and Anaphylaxis

• Hypersensitivity reactions, including anaphylaxis, have been reported during Infusion
• ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis
• Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs

Patient Counseling Information

• ANTHIM

Package Inserts

Obiltoxaximab